NephJC
NephJC is a nephrology journal club that uses Twitter to discuss the research, guidelines, and editorials that drive nephrology. COVID19 and the…
NephJC is a nephrology journal club that uses Twitter to discuss the research, guidelines, and editorials that drive nephrology. COVID19 and the…
C3 glomerulopathy (C3G) is a rare disease resulting from dysregulation of the alternative pathway of complement. C3G includes C3 glomerulonephritis (C3GN) and dense deposit disease…
Is Apolipoprotein E a new biomarker for DDD and C3GN? NSMC Intern Dr Jasmine Sethi decodes the recent study visually
This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
PubMed® comprises more than 36 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text…
This week, we will discuss another IgA Nephropathy trial – Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
PubMed® comprises more than 36 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text…
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because…
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients…
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy – should it upstage humble prednisone?